All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
170 results
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Radiation and Cisplatin with or without Triapine in Newly Diagnosed Cervical Cancer
Protocol No
NRG-GY006
Sub Category
Gynecologic Cancers
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects with Multiple Myeloma
A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma
Protocol No
AMGEN-20170122-AMG701
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies
Protocol No
ABBVIE-M15-913
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
A Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients with Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
Protocol No
WON-UW16112-TNBC
Sub Category
Breast Cancers
A Randomized, Placebo-controlled, Double-blind, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (Nab-paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-positive, Triple-negative Breast Cancer
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Protocol No
UC-16-0403-TNBC
Sub Category
Breast Cancers
Monoclonal Antibody-Based Sequential Therapy For Deep Remission In Multiple Myeloma MASTER TRIAL
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)
Protocol No
UAB-1735-MASTER
Sub Category
Hematologic/Blood Related Cancers
A Pivotal (phase IIb), Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Protocol No
SOLIGENIX-IDR-OM-02
Sub Category
Head and Neck Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Protocol No
SUTRO-STRO-002-GM1
Sub Category
Gynecologic Cancers
A Phase 1b Study of SAR650984 (Isatuximab) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)
Protocol No
SANOFI-TCD14079
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Protocol No
BI-1381-REFMAL485
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Protocol No
RTOG-1008
Sub Category
Head and Neck Cancers
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Protocol No
ALCHEMIST-A151216
Sub Category
Thoracic Cancers
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Protocol No
G1THERAPEUTICS-G1T38-03
Sub Category
Thoracic Cancers
Early Phase/Multiple Disease Site Cancers
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Protocol No
HOFFMANN-WO39608-MORPHEUS
Sub Category
Gastrointestinal Cancers
Early Phase/Multiple Disease Site Cancers
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Protocol No
ADCT-402-201-DLBCL
Sub Category
Hematologic/Blood Related Cancers